Predictive Value of the FORE-SIGHT™ Monitor for Hemodynamic Deterioration

May 14, 2019 updated by: Geert Meyfroidt, MD, PhD, KU Leuven

Validation of the Predictive Value of the FORE-SIGHT™ Monitor for Early Detection of Hemodynamic Deterioration After Pediatric Cardiac Surgery. A Data-mining Study.

The postoperative period after congenital heart surgery in children can be a very critical episode, where it is of utmost importance to closely monitor the circulation in these patients. Invasive hemodynamic monitoring tools available in the adult population, are often not suitable to use in small children.

The Fore-Sight(TM) is a non-invasive monitor for brain tissue oxygenation (SctO2), by projecting harmless near-infrared light trough the skin, skull, and brain via a disposable sensor that is applied on the forehead of patients. In many centres, the Fore-Sight (TM) is part of the routine monitoring of children during cardio-pulmonary bypass for congenital heart surgery. Although the monitor has not been tested for this purpose, it is often continued in the postoperative phase in the intensive care unit (ICU), where it is used to monitor the hemodynamic situation of the patient.

The purpose of the present study is to examine and validate the use of the Fore-Sight monitor for hemodynamic monitoring of children in the postoperative phase after cardiac surgery.

The study hypothesis is whether SctO2 desaturations are predictive for future hemodynamic deterioration of the patient, and whether these SctO2 desaturations are predictive for the outcome of these patients.

Study Overview

Detailed Description

  1. Background

    Accurate hemodynamic monitoring often requires the use of invasive tools or catheters. Many of these tools, available for adults, cannot be used for critically ill infants and children, because of their size, and because these invasive techniques carry a high risk of complications. Non-invasive monitoring techniques that allow for detecting critical hemodynamic states are of high interest in this population.

    FORE-SIGHT™ is a non-invasive tool to measure cerebral tissue oxygen saturation. Cerebral tissue oxygen saturation (SctO2) values are important to clinicians because cerebral hypoxia (lack of oxygen supply to brain tissue) is one of the leading causes of brain injuries that occur in many surgical and clinical situations. The FORE-SIGHT™ Cerebral Oximeter utilizes optically-based Near Infra-Red Spectroscopy (NIRS) technology to monitor absolute SctO2. It works by projecting harmless near infra-red light through the scalp and skull and into the brain via a disposable sensor on the patient's forehead. The device measures the light that is returned to detectors on the sensor and analyzes this information utilizing patented algorithms to determine absolute cerebral tissue oxygen saturation levels. The FORE-SIGHT™ is designed to monitor SctO2 in a continuous way, and provides clinicians an opportunity to intervene before damage to the brain occurs. The monitor is currently part of the standard monitoring for children undergoing cardiopulmonary bypass, in the operating theatre, and is often continued in the postoperative phase in the pediatric intensive care unit (PICU) of the university hospitals Leuven.

    Several studies have pointed to the potential advantages of SctO2 monitoring in the peri-operative phase after cardiac or abdominal surgery in adults [1,2,3,4], as well as in children undergoing surgical corrections of congenital cardiac defects [5,6,7]. Low SctO2 values are associated with worse outcome, and correspond with data from other monitors indicating that the oxygen content of the brain at that time is insufficient. In particular, the duration of SctO2 desaturations below 55%, 60%, and 65%, is predictive for postoperative complications [8]. These studies, however, have only analyzed the use of NIRS as a tool to monitor the brain at times when it is at the highest risk, during complex surgery with a compromised circulation. Although there is no evidence that has demonstrated that decision making based on NIRS data is favorable for patient outcome, many centers use NIRS as a monitoring tool outside of the surgical environment.

    Because the brain is very sensitive to changes in oxygenation, monitoring of SctO2 might provide an indication of critical changes in the hemodynamic state of the patient, and thus serve as a monitor for the general hemodynamic status of the patient. The present study wishes to examine the added value of SctO2 monitoring over the routine monitoring of pediatric patients in PICU, in the postoperative phase after cardiac surgery. Ideally, in order to be of added value, SctO2 changes should precede an episode of hemodynamic deteriorations.

    Prediction is at the heart of intensive care medicine, where physicians make use of their medical knowledge and all the patient-related data in order to foresee changes in the patient's condition, and administer the appropriate (preventive) treatments. An intensive care unit (ICU) is a very data-rich environment with several information sources, such as admission records, medical history, laboratory analyses of samples, medication and treatment records, and monitoring of vital signals. A Patient Data Management System (PDMS) (MetaVision®, iMD-Soft®, Boston, MA) was installed in our ICU starting in February 2006. This PDMS software automatically collects and integrates the data from the multiple information sources. One of the benefits of having all patient-related data in an integrated format is that it can be readily analyzed through the use of computational techniques in general and data mining in particular. These techniques make use of the information in large databases to automatically generate models that can be used for prediction (e.g. to predict a patient's probability of survival in ICU). In previous studies our research group has shown the high predictive performances than can be obtained with data mining models in the intensive care domain.

    In this study we will make use of data mining techniques to assess the predictive power of SctO2-monitoring for future hemodynamic deterioration of the PICU patient after cardiac surgery, by analyzing data collected in the PDMS, including the FORE-SIGHT™ NIRS.

  2. Aims of the project

    • To assess the independent predictive power of the FORE-SIGHT™ NIRS signal for future hemodynamic deterioration of critically ill infants and children, in the postoperative phase after cardiac surgery.

    • To assess the predictive power of the FORE-SIGHT™ NIRS signal for outcome in critically ill infants and children, in the postoperative phase after cardiac surgery.

  3. Study design

Prospective, observational, non-interventional study. All eligible children will be monitored with the FORE-SIGHT™, from admission until they are weaned off mechanical ventilation. Typically, patients admitted after cardiac surgery in the PICU of the university hospitals Leuven are mechanically ventilated between 12 hours and two weeks [8].

The FORE-SIGHTTM SctO2 signal will be blinded to the bedside clinician and will be stored in the PDMS system for analysis. The first 20 minutes of data after arrival to the ICU will not be used for the analysis, since during this time the patient typically stabilizes to the new environment after transport, and the data are therefore not characteristic of the ICU stay.

Data from these patients will be used for analysis, to build predictive models. A copy of the PDMS database, after removal of all data that refer to the identity of the patients, will be used for data analysis. Data mining models, such as simple logistic regression models, but also more advanced machine learning techniques (models automatically learned by a computer algorithm, such as Decision Tree models [9], Bayesian Networks, Gaussian Processes, Support Vector Machines, …), will assess the independent predictive power of the FORE-SIGHT™ signal over the routinely monitored data.

1. FORE-SIGHT™ for early detection of future hemodynamic instability.

First, models will be built to assess the independent predictive power of the FORE-SIGHT™ signal to detect episodes of hemodynamic instability 10 minutes in advance.

Since cardiac output is not directly measured invasively in children, such an episode is evidenced by indirect signs. If one of more of the following criteria is met, this is considered to be an episode of hemodynamic instability.

  1. Hemodynamic monitoring • Heart Rate >160 or <90, for at least 5 consecutive minutes • Systolic Blood Pressure < 55 (infants) or < 65 (children) , for at least 5 consecutive minutes
  2. Point of care laboratory analysis

    • Venous Saturation (SvO2) <55 (when cyanogenic cardiopathy is present), or <65 (in all other patients)

    • Lactate > 2 mmol/L on arterial blood gas sampling

  3. Clinical observation • Urine Output rate < normal rate of 0.5 ml/kg/h over 2 consecutive hours

2. FORE-SIGHT™ for prediction of outcome. Second, models will be built to assess whether the FORE-SIGHT™ signal is predictive for hospital and ICU Length of Stay (LOS ), mortality, and duration of (invasive or non-invasive) mechanical ventilator support.

In order to assess predictive performance for the 2 predictive tasks, the following statistics will be used: the positive predictive value, the area under the ROC curve (AUROC), the Hosmer-Lemeshow statistic, calibration-in-the-large, calibration-slope and Brier scores.

The positive predictive value is the proportion of positive instances that are correctly classified. It reflects the probability that a positive result corresponds to the underlying condition being tested for.

The AUROC is a measure of the model's ability to discriminate between positive and negative instances. Usually AUROC as evaluation is preferred above accuracy as it allows to trade off the possibly different costs of incorrectly classifying a negative instance as positive, or equivalently to tradeoff between the model's sensitivity and specificity.

The Hosmer-Lemeshow statistic, calibration-in-the-large and the calibration-slope are used to determine whether a model is well calibrated. These test assess whether the observed event rates match expected event rates in subgroups of the population. Models for which expected and observed event rates in subgroups are similar are said to be well calibrated.

Overall model performance will be assessed with the Brier Score and its normalized version, the Brier Scaled Score. Accurate models have a low overall prediction error and therefore a low Brier Score (below the base case value for each task).

4 Study population

All children younger than 12 years of age, admitted to the PICU of the Leuven University hospitals Leuven after cardiac surgery are eligible for the study, if they meet the following inclusion criteria:

  • Mechanically ventilated upon ICU admission or intubated after admission
  • Arterial line in place.
  • Expected to stay at least 24h in the PICU.

Patients with actual or potential brain damage, such as traumatic brain injury patients, patients with brain tumors, or patients after cardiopulmonary resuscitation (CPR) are excluded. Patients with a condition or a wound that prohibits the placement of a forehead sensor are also excluded.

The study will collect data for a period of 1,5 year. 300 critically ill children will be recruited. Approximately 20% of the PICU patients exhibit clinical deterioration events, and with a median (IQR) length of stay of 3 (2-7) days [8] and at least one event per day, we expect a minimum of 180 events of clinical deterioration in the yearly population. From previous studies with a similar event distribution [15,16] we expect our models to result in a sensitivity (and specificity) of at least 0.8, with an alpha error of 5% and a statistical power of 80%.

The study will therefore have the required statistical power to detect the potential of the FORE-SIGHT™ NIRS signal in predicting clinical deterioration.

Study Type

Observational

Enrollment (Actual)

300

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Leuven, Belgium, 3000
        • Department of Intensive Care Medicine, University Hospitals Leuven

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

No older than 12 years (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

All children younger than 12 years, admitted after cardiac surgery in the pediatric intensive care unit (PICU) of the university hospitals Leuven, Belgium, on mechanical ventilation or intubated after admission. Children are monitored with the FORE-SIGHT™, from admission until they are weaned off mechanical ventilation (typically, most of these patients are mechanically ventilated between 12 hours and two weeks after ICU admission).

Description

Inclusion Criteria:

  • younger than 12 years of age
  • Mechanically ventilated upon ICU admission or intubated after admission
  • arterial line in place
  • expected to stay at least 24 hous in the PICU

Exclusion Criteria:

  • actual or potential brain damage (such as traumatic brain injury, brain tumors, or patients after cardiopulmonary resuscitation (CPR), ...).
  • patients with a condition or a wound that prohibits the placement of a forehead sensor are also excluded.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The Accuracy to Predict Acute Kidney Injury (AKI) Per Patient, 6 Hours Before This Clinical Event (AKI) Occurs
Time Frame: Predictive window of 6 hours before AKI occurence

Defined according to the Kidney Disease: Improving Global Outcome criteria (AKI stage 2 or 3)

  • serum creatinine (SCr) level ≥ 2 times the baseline level, or
  • urine output (UO) < 0.5 ml/kg/hour for ≥ 12 hours, or
  • provision of dialysis
Predictive window of 6 hours before AKI occurence

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Hospital Length of Stay
Time Frame: Hospital discharge
participants will be followed for the duration of hospital stay, an expected average of 1-2 weeks
Hospital discharge
Intensive Care Unit Length of Stay
Time Frame: Intensive care unit discharge
participants will be followed for the duration of hospital stay, an expected average of 1-2 weeks
Intensive care unit discharge
Duration of Mechanical Ventilation
Time Frame: ICU discharge
participants will be followed for the duration of hospital stay, an expected average of 1-2 weeks
ICU discharge
Hospital Mortality
Time Frame: Hospital discharge
participants will be followed for the duration of hospital stay, an expected average of 1-2 weeks
Hospital discharge

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Geert JP Meyfroidt, MD, PhD, Department of Intensive Care Medicine, University Hospitals Leuven, Belgium and Laboratory of intensive care medicine, department of cellular and molecular medicine, Biomedical sciences group, KULeuven - University, Belgium

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2012

Primary Completion (Actual)

January 1, 2016

Study Completion (Actual)

January 1, 2016

Study Registration Dates

First Submitted

October 10, 2012

First Submitted That Met QC Criteria

October 12, 2012

First Posted (Estimate)

October 15, 2012

Study Record Updates

Last Update Posted (Actual)

May 15, 2019

Last Update Submitted That Met QC Criteria

May 14, 2019

Last Verified

May 1, 2019

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pediatric Congenital Heart Surgery

Clinical Trials on Cerebral tissue oxygen saturation monitoring, blinded

Subscribe